ORBIMED ADVISORS LLC

Q2 2020 13F-HR Holdings

Location
New York, NY
Holdings as of
6/30/2020
Date filed
8/14/2020
Form type
13F-HR
Num holdings
135
Total value ($000)
$7,102,993
Net value change ($000)
+1,152,631 (19.4%)
New positions
22
Sold out positions
29
Turnover %
16.3%
Sector allocation + QoQ delta (equities-only)

Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown

Prev filing: 5/15/2020 Next filing: 11/16/2020 SEC filing

Snapshot: Change Analysis

Compared to Q1 2020
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
BNR 128,191 NEW
SpringWorks Therapeutics, Inc. 111,095 55.6%
RPTX 106,285 NEW
ORIC 98,558 NEW
Horizon Therapeutics Public Ltd Co 90,037 129.8%
PASG 80,630 73.5%
KROS 62,995 NEW
NTRA 61,631 61.7%
Fusion Pharmaceuticals Inc. 56,337 NEW
ALXN 55,999 30.1%
Top Reduces (Value $000, Stocks/ETFs)
ASND -139,028 -37.6%
PFE -98,315 -100.0%
GILD -95,191 -86.6%
HCA -63,776 -100.0%
SYK -61,784 -100.0%
ALEC -54,910 -27.3%
PTCT -51,245 -100.0%
BMRN -45,672 -100.0%
NXTC -42,373 -42.2%
ARVN -39,113 -97.5%
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000): 29,327 (0.4% of total reported value)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type